Delving into the Latest Updates on Cyclosporine (Huons) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Ciclosporin (Huons), Clacier

+ [2]

Target

CaN

Action

inhibitors

Mechanism

CaN inhibitors(Calcineurin inhibitors)

Therapeutic Areas

Eye Diseases

Active Indication

Xerophthalmia

Inactive Indication-

Originator Organization

Huons Co., Ltd.

Active Organization

Huons Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

South Korea (26 Nov 2018),

Xerophthalmia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC62H111N11O12

InChIKeyPMATZTZNYRCHOR-CGLBZJNRSA-N

CAS Registry59865-13-3

Five polypeptides with a potential umami taste were isolated and purified from Yanjin black bone chicken. However, the flavor characteristics and umami mechanism have not been clarified. The umami properties of these five peptides were investigated in this work using a range of analytical techniques, computer simulation, and sensory evaluation. HE-10 and TP-7 exhibited the strongest umami flavors. Furthermore, dose-response experiments showed that the umami peptides enhanced umami by generating peptide mineral chelates. Environmental scanning electron microscopy (ESEM) microstructural analyses supported this finding. The molecular docking results indicated that the five polypeptides bind to four critical amino acid residues, namely Glu217, Glu148, Asp216, and His145, of the T1R1/T1R3 receptor. The binding occurred through van der Waals, electrostatic interactions, hydrogen bonding, and hydrophobic interactions. The main surface forces implicated include aromatic interactions, hydrogen bonding, hydrophilicity, and solvent accessibility.

31 Dec 2024·Renal Failure

Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies

Article

Author: Li, Yanchun ; Shen, Yang ; Ma, Lijie ; Sun, Qianmei ; Li, Xue

BACKGROUNDIdiopathic membranous nephropathy (IMN) with deposits of phospholipase A2 receptor (PLA2R) antigen in glomerular tissue (GAg+) but no circulating serum PLA2R antibody (SAb-) has been reported. However, little is known about the clinicopathological characteristics and prognosis of this subtype.METHODSA total of 74 IMN patients with GAg + identified by kidney biopsy were enrolled in this study. We categorized patients into two groups based on the presence or absence of serum PLA2R antibody. Data on clinical features, pathological features, and outcomes were collected. Kaplan-Meier analysis of complete remission (CR) and partial remission (PR) comparing SAb-/GAg + and SAb+/GAg + patients. Cox proportional hazards models was used to examine factors associated with CR and PR.RESULTSAmong 74 IMN patients, 14 were SAb-/GAg+. Compared with SAb+/GAg + patients, SAb-/GAg + patients presented with higher levels of albumin, lower levels of cholesterol and low density lipoprotein cholesterol (all p < .01), but similar pathological manifestations of kidney biopsy. Multivariate logistic analyses indicated that low albumin (0.79 [95%CI: 0.66-0.95], p = .01) and high cholesterol (1.81 [95%CI: 1.02-3.19], p = .04) were correlated with seropositivity of PLA2R antibody. SAb-/GAg + patients exhibited a significantly higher probability of CR (p = .03) than patients who were SAb+/GAg+. However, no difference was found in the PR rate. Cox regression analyses showed that compared to SAb+/GAg + patients, SAb-/GAg + was more predictive of complete remission (4.28 [95%CI: 1.01-18.17], p = .04).CONCLUSIONIMN with PLA2R staining on kidney biopsy but without serum PLA2R antibody has milder clinical manifestations and a better prognosis.

31 Dec 2024·Hematology

High- vs regular-dose recombinant human thrombopoietin plus cyclosporine A in patients with newly diagnosed non-severe aplastic anemia: a retrospective cohort study

Article

Author: Yang, Yuan ; Han, Bing ; Chen, Miao ; Yang, Chen ; Hu, Qinglin

BACKGROUNDCyclosporine A (CsA) and regular doses of recombinant human thrombopoietin (rhTPO) can accelerate platelet recovery in patients with non-severe aplastic anemia (NSAA). However, it is unclear whether CsA plus rhTPO at a higher dose can further increase the efficacy.METHODSData from patients with newly diagnosed NSAA, who had been treated with CsA in combination with different doses of rhTPO between February 2021 and August 2021 at Peking Union Medical College Hospital, were reviewed. All the enrolled patients had been treated with CsA at 3-5 mg/(kg/d), and patients were further classified into high-dose (with rhTPO 30000U qd × 14 days for 2 months) group or regular-dose (with rhTPO 15000U qd × 7days for 3 months) group. The treatment response and therapy-related adverse events were compared.RESULTS36 patients including 16 (44.4%) in the high-dose and 20 (55.6%) in the regular-dose group were enrolled. The baseline characteristics were compatible between the two groups. The platelet counts were significantly higher at 1/3/6 months in the high-dose group (p = 0.028, 0.0063 and p = 0.040, respectively). The high-dose group had a significantly shorter time to platelet transfusion independence ([1 (0.5-6) months vs 2.5 (1-12) months, p = 0.040]). There was no significant difference in overall response and complete response rate between the two groups at 1/3/6/12 months (p > 0.05). Treatment-related morbidities were similar between the two groups (p > 0.05).CONCLUSIONSAdding a higher dose of rhTPO can further accelerate platelet recovery and platelet transfusion independence in patients with newly diagnosed NSAA.

100 Deals associated with Cyclosporine (Huons)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB00091

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Xerophthalmia	South Korea	Huons Co., Ltd.	26 Nov 2018

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dry Eye Syndromes	Discovery	-	Huons Co., Ltd.	01 May 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00987480 (CTgov)	Phase 2	Leukemia \| Myelodysplastic Syndromes \| Fanconi Anemia	45	CliniMACS device+fludarabine+Busulfan+cyclosporine.+cyclophosphamide	uorohfyoun(jjfublgjms) = qslhwdslts ubqotuwmyf (ouyibxktvu, pqqmjrvcxa - tlcsdmjhbf) View more	-	10 Jul 2018
NCT00974142 (CTgov)	Phase 1/2	Pulmonary Disease, Chronic Obstructive	43	Cyclosporine (Cyclosporine)	pesdktqrdk(mibxkzgcnz) = sqrxpsuaaj togvroreal (xkrvqmwcct, gsnhpuwygj - tsgzkvgypo) View more	-	09 May 2018
				Placebo (Placebo)	pesdktqrdk(mibxkzgcnz) = gjjumkiejj togvroreal (xkrvqmwcct, ddxnasmnpr - jtafpcynev) View more
NCT00609739 (CTgov)	Phase 1/2	Juvenile Myelomonocytic Leukemia	1	umbilical cord blood transplantation+methylprednisolone+Cis-Retinoic acid+cyclosporine+Filgrastim+mitoxantrone hydrochloride+methotrexate+Cytarabine	(ycnfrujigc) = musbebcnaj smvlyektyt (uuxyljhfrz, xxcjpzfjlw - cdhmmuyrfx) View more	-	02 Mar 2012
NCT00154284 (CERTES02, CTgov)	Phase 3	Renal transplant rejection	114	Steroid+Cyclosporine (Neoral)+Basiliximab (Simulect)+Everolimus (Certican) (Everolimus (Certican) With Cyclosporine (Neoral) Continuation)	meswkhgdhx(ypcsdddpnf) = qhdebcmtft lfudzecrrg (boeouscgxg, llpalkrmxp - oupxooqxfq) View more	-	11 Mar 2011
				Steroid+Cyclosporine (Neoral)+Basiliximab (Simulect)+Everolimus (Certican) (Everolimus (Certican) With Cyclosporine (Neoral) Withdrawal)	meswkhgdhx(ypcsdddpnf) = wolpmxmpyf lfudzecrrg (boeouscgxg, fyflvmvghv - otvwedlrqj) View more
NCT00419926 (CTgov)	Phase 4	-	313	Cyclosporine (Neoral)+Prednisone+Enteric-coated mycophenolate sodium (Myfortic) (Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen)	viarqvpcvc(npwyiikhlz) = grwutaxexn qhenquklhk (axmpawkiff, hjdemsspwo - thttratowo) View more	-	11 Jan 2011
				Cyclosporine (Neoral)+Prednisone+Enteric-coated mycophenolate sodium (Myfortic) (Standard Mycophenolate Sodium (Myfortic) Dosing Regimen)	viarqvpcvc(npwyiikhlz) = vxgximvjuf qhenquklhk (axmpawkiff, cewnhqhdbu - mqfarbgkrv) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data